Episode 46: Can you harness capitalism to accelerate health equity? Squire Servance of Syridex Bio says yes
Health equity is a hot topic these days. There’s no question that certain populations have better and more frequent access to healthcare – not to mention sometimes dramatic variations in the quality of care. Health inequities drive roughly $320 billion in annual healthcare spending – money that could be better spent elsewhere if we could just figure out a way to address this issue. While there is no silver bullet to addressing health equity, Squire Servance, founder and managing partner at Syridex Bio, is trying to do his part. Syridex Bio is an impact-driven, life sciences-focused firm investing in therapies that address the needs of underserved communities. Squire joins Justin for the final episode of Definitively Speaking to explore the social and economic costs of healthcare disparity, the challenge of developing treatments for underserved groups, and why investing in health equity is both good business sense and just plain good.
Justin and Squire discuss the root causes of health inequity in the U.S. and examine how Syridex Bio harnesses capitalism to develop treatments for patient demographics that the market has largely ignored. They discuss the challenge of securing market access, the push-pull relationship between on- and off-patent drugs, and why it’s worth being optimistic about health equity.
Plus, Justin says goodbye to the incredible guests, listeners, and production team of Definitively Speaking as we bring this edutaining series to a close.
To learn more about Definitive Healthcare, please visit us at definitivehc.com.
